Get the Stockscreener App
0.70
1.41%
-0.01
After Hours:
.70
Promis Neurosciences Inc stock is traded at $0.70, with a volume of 49,930.
It is down -1.41% in the last 24 hours and down -23.87% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$0.71
Open:
$0.75
24h Volume:
49,930
Relative Volume:
0.84
Market Cap:
$22.88M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-3.507
EPS:
-0.1996
Net Cash Flow:
$-22.23M
1W Performance:
-12.52%
1M Performance:
-23.87%
6M Performance:
-46.56%
1Y Performance:
-66.51%
1-Day Range:
$0.6208
$0.76
1-Week Range:
$0.6208
$0.8446
52-Week Range:
$0.6208
$2.61
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.70 | 22.88M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Promis Neurosciences Inc Stock (PMN) Latest News
ProMIS Neurosciences stock hits 52-week low at $0.62 - Investing.com India
ProMIS Neurosciences stock hits 52-week low at $0.62 By Investing.com - Investing.com South Africa
ProMIS Neurosciences’ (PMN) “Buy” Rating Reiterated at Guggenheim - Defense World
ProMIS Neurosciences begins Alzheimer's trial dosing - Investing.com India
ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial - TipRanks
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times
ProMIS Neurosciences begins Alzheimer’s trial dosing - Investing.com
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for ... - The Bakersfield Californian
Multiple System Atrophy Clinical Trials and Pipeline 2025: EMA, - openPR
ProMIS Neurosciences Announces COO Position Termination - TipRanks
ProMIS Neurosciences stock hits 52-week low at $0.85 By Investing.com - Investing.com Nigeria
ProMIS Neurosciences dismisses COO position - MSN
ProMIS Neurosciences announces COO departure - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.85 - Investing.com
Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel - GlobeNewswire
StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside ProMIS's Game-Changing Approach to Neurodegenerative Diseases: CEO Reveals Latest Developments - StockTitan
ProMIS Neurosciences Updates Corporate Presentation in Recent 8-K Filing - Defense World
Vanda Pharmaceuticals Files for New Drug Application for Tradipitant for Motion Sickness Treatment - Defense World
ProMIS Neurosciences Highlights Neurodegenerative Disease Focus - TipRanks
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial - MSN
LANTRONIX Appoints Brent Stringham as Chief Financial OfficerIRVINE, Calif. – Lantronix, Inc. (NASDAQ: LTRX), a prominent provider of IoT compute and connectivity solutions, has announced the appointment of Brent Stringham as its new Chief Financial - ETF Daily News
ProMIS Neurosciences Issues Letter to Shareholders - Markets Insider
Crude Oil WTI (CLN25) Quote - The Globe and Mail
Crude Oil Brent (F) (QAJ23) Quote - The Globe and Mail
ProMIS Neurosciences Launches Phase 1b Trial for Alzheimer’s - TipRanks
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease - The Manila Times
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - The Manila Times
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences faces Nasdaq delisting over share price - Investing.com
Nonfat Dry Milk (DFZ25) Quote - The Globe and Mail
Berkshire Hathaway Cl B (BRK-B-N) QuotePress Release - The Globe and Mail
ProMIS Neurosciences (NASDAQ:PMN) Shares Up 2.8% – Should You Buy? - Defense World
ProMIS Neurosciences stock hits 52-week low at $0.88 By Investing.com - Investing.com Nigeria
ProMIS Neurosciences stock hits 52-week low at $0.88 - Investing.com
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Short Interest Down 16.6% in November - Defense World
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewswire
ProMIS Neurosciences stock hits 52-week low at $0.91 - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.91 By Investing.com - Investing.com Australia
13th Alzheimers and Parkinsons Drug Development Summit - PharmiWeb.com
ProMIS Neurosciences Announces Third Quarter Financial Results and Recent HighlightsOn November 14, 2024, ProMIS Neurosciences Inc. (Nasdaq: PMN) shared its financial outcomes for the third quarter ended September 30, 2024. The company provide - Defense World
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.13%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):